Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345397 | 0.84 | MEN1 (0.38) | SCDSCD5RIPK1POLBMEN1 | |
| SCHEMBL345321 | 0.80 | RBP4 (0.39) | RBP4 | |
| SCHEMBL345161 | 0.74 | MEN1 (0.36) | MEN1KMT2AGFER | |
| SCHEMBL15662150 | 0.72 | MEN1 (0.47) | MEN1KMT2AGFER | |
| Hydrochloric Acid SCHEMBL345732 | 0.70 | SMYD3 (0.38) | RIPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL346479 | 0.68 | TSHR (0.42) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL9993658 | 0.67 | HRH3 (0.38) | RIPK1 | |
| SCHEMBL16162195 | 0.67 | MEN1 (0.51) | MEN1KMT2AGFER | |
| SCHEMBL345182 | 0.66 | CHRM4 (0.45) | RBP4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1267034 | 0.65 | MEN1 (0.52) | MEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | SCD 4792/4885SCD5 4185/4885RBP4 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.